34 related articles for article (PubMed ID: 36175810)
21. [Respiratory care in spinal muscular atrophy in the new therapeutic era].
Palomino MA; Castiglioni C
Rev Chil Pediatr; 2018 Dec; 89(6):685-693. PubMed ID: 30725056
[TBL] [Abstract][Full Text] [Related]
22. Nusinersen: A Treatment for Spinal Muscular Atrophy.
Claborn MK; Stevens DL; Walker CK; Gildon BL
Ann Pharmacother; 2019 Jan; 53(1):61-69. PubMed ID: 30008228
[TBL] [Abstract][Full Text] [Related]
23. Nusinersen for the treatment of spinal muscular atrophy.
Chiriboga CA
Expert Rev Neurother; 2017 Oct; 17(10):955-962. PubMed ID: 28884620
[TBL] [Abstract][Full Text] [Related]
24. Use of MFM-20 to monitor SMA types 1 and 2 patients treated with nusinersen.
Le Goff L; Seferian A; Phelep A; Rippert P; Mathieu ML; Cances C; de Lattre C; Durigneux J; Gousse G; Vincent-Genod D; Ribault S; Gomez Garcia de la Banda M; Quijano-Roy S; Sarret C; Servais L; Vuillerot C
Neurol Sci; 2023 Jan; 44(1):329-337. PubMed ID: 36175810
[TBL] [Abstract][Full Text] [Related]
25. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments.
Dangouloff T; Botty C; Beaudart C; Servais L; Hiligsmann M
Orphanet J Rare Dis; 2021 Jan; 16(1):47. PubMed ID: 33485382
[TBL] [Abstract][Full Text] [Related]
26. Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis.
Coratti G; Cutrona C; Pera MC; Bovis F; Ponzano M; Chieppa F; Antonaci L; Sansone V; Finkel R; Pane M; Mercuri E
Orphanet J Rare Dis; 2021 Oct; 16(1):430. PubMed ID: 34645478
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of risdiplam in spinal muscular atrophy: A systematic review and meta-analysis.
Pascual-Morena C; Martínez-Vizcaíno V; Cavero-Redondo I; Martínez-García I; Moreno-Herráiz N; Álvarez-Bueno C; Saz-Lara A
Pharmacotherapy; 2024 Jan; 44(1):97-105. PubMed ID: 37574770
[TBL] [Abstract][Full Text] [Related]
28. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data.
Erdos J; Wild C
Eur J Paediatr Neurol; 2022 Jul; 39():1-10. PubMed ID: 35533607
[TBL] [Abstract][Full Text] [Related]
29. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison.
Ribero VA; Daigl M; Martí Y; Gorni K; Evans R; Scott DA; Mahajan A; Abrams KR; Hawkins N
J Comp Eff Res; 2022 Apr; 11(5):347-370. PubMed ID: 35040693
[No Abstract] [Full Text] [Related]
30.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
31.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
